Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma

We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma.

Questions

1. What is the rationale for the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma, and what are the limitations of this regime? (0:06)

2. What were the aims and design of the ENDURANCE trial? (1:38)

3. What were the major efficacy findings of this trial? (3:12)

4. What was the safety profile of this combination and what were the findings in terms of cardiovascular events? (4:34)

5. Despite these promising findings, multiple myeloma remains incurable. What future strategies are likely to further improve outcomes in the coming years? (5:56)

Speaker disclosure: Shaji Kumar has received research funding for clinical trials to the institution from Celgene, Takeda, Janssen, BMS, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen, Tenebio and Carsgen. He has received consulting/advisory board participation fees to his institution from Celgene, Takeda, Janssen, Abbvie, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Genecentrix and Cellectar.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.